What happened
Original notice title
ICA Health, LLC/Future Formulations, LLC MARCS-CMS 614383, September 20, 2021
From the archived source record
The same cortisol-regulated changes designed to help you deal with an acute stressor become harmful when stress is frequent or chronic over extended periods of time. Chronically elevated: o Blood sugar produces increased insulin, insulin resistance and increased abdominal fat, which can potentially develop into metabolic syndrome and diabetes o Blood pressure and heart rate contribute to cardiovascular disease o Excitatory brain stimulation can lead to anxiety and mood disorders, cognitive and memory impairment, sleep problems … o Stress hormones suppress immune function and makes cells less responsive to the anti-inflammatory actions of cortisol, increasing inflammation.” Dr. Wilson on www.adrenalfatigue.org: “I continue to pursue this mission through . . . developing equally unique and effective formulas targeted to areas of health adversely affected by stress, such as blood sugar balance and immune function.” Webpage Article titled “How Stress Affects the Body” on www.adrenalfatigue.org: “How Stress Affects the Body” o “depression…” o “higher cholesterol, high blood pressure, increased risk of heart attack and stroke” o “increased inflammation … pains…” o “decreased immune function … increased risk of becoming ill…” Webpage Article titled “Stress and Health” on www.adrenalfatigue.org: “Stress and Immune Function . . . . Chronic illness and toxic treatments like chemotherapy are major stressors that the adrenals must respond to. . . . A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Wilson’s Nat-Stim fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].
What the official notice says to do
Check the original notice for the instructions that apply to the named product, company, and affected lots.
Read the official notice →Status and source details
- Status recorded in the archive
- FDA closeout listed
- Source checked
- Jul 16, 2026
- Record revision
- 1c41f7dfe5f6
This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.
Sources, dates, and coverage →